Transthyretin Amyloidosis Treatment Market Report Scope & Overview:

The Transthyretin Amyloidosis Treatment Market was valued at USD 8.95 Billion in 2025 and is expected to reach USD 35.10 Billion by 2035, growing at a CAGR of 14.64% from 2026–2035.

Transthyretin amyloidosis is a disease that used to be treated mostly by managing symptoms, since there wasn't much anyone could do about the underlying cause: a misfolded protein called transthyretin building up as amyloid deposits in the heart and peripheral nerves. That's changed pretty dramatically over the past decade. Gene-silencing drugs like patisiran and vutrisiran now stop the liver from producing so much of the problem protein in the first place, and TTR stabilizers work through a different mechanism to keep the protein from misfolding at all. Both approaches represent something genuinely new for a disease that, not that long ago, mostly meant watching a patient's heart function or nerve damage get worse over time with no real way to intervene. Better diagnostic tools, especially nuclear cardiac imaging that can identify ATTR-CM without a biopsy, have also meant a lot more patients are actually getting diagnosed now instead of living with an undiagnosed condition for years.

In November 2024, the FDA approved Alnylam Pharmaceuticals' vutrisiran, marketed as Amvuttra, as a subcutaneous RNA interference therapy for cardiomyopathy caused by wild-type or hereditary transthyretin-mediated amyloidosis in adult patients. It was a meaningful expansion for a drug that had already been approved for the polyneuropathy form of the disease, and it gave physicians another option for a cardiac condition that, until fairly recently, had very few disease-modifying treatments to offer patients at all.

Market Size and Forecast

• Market Size in 2026E: USD 10.26 Billion

• Market Size by 2035: USD 35.10 Billion

• CAGR: 14.64% from 2026 to 2035

• Fastest Growing Region: Asia Pacific

• Largest Region: North America

To Get more information on Transthyretin Amyloidosis Treatment Market - Request Free Sample Report

Transthyretin Amyloidosis Treatment Market Trends

• RNA interference therapies keep expanding their approved indications, moving from purely neurological presentations of ATTR into cardiomyopathy as clinical evidence accumulates.

• Nuclear cardiac imaging, particularly technetium pyrophosphate scans, is letting physicians diagnose ATTR-CM without a biopsy, which is quietly driving a lot more patients into diagnosis and treatment than would've happened a decade ago.

• Pipeline activity remains unusually active for a rare disease space, with next-generation candidates like acoramidis and eplontersen working through trials and regulatory review.

• Wild-type ATTR diagnosis is climbing as clinicians get better at recognizing it in older heart failure patients, a population that used to get misdiagnosed or overlooked fairly often.

• Patient access programs and genetic counseling services tied to hereditary ATTR are becoming a more standard part of how manufacturers support newly diagnosed families, not just an afterthought.

U.S. Transthyretin Amyloidosis Treatment Market Outlook

The U.S. Transthyretin Amyloidosis Treatment Market was valued at approximately USD 3.55 Billion in 2025 and is expected to reach approximately USD 13.49 Billion by 2035, growing at a CAGR of approximately 14.27%.

The U.S. dominates the North American market by a wide margin, and the reasons aren't especially surprising: a healthcare infrastructure built to support complex specialty drug administration, early access to newly approved therapies, and a concentration of pharmaceutical companies with real depth in genetic and orphan disease work. Between 5,000 and 7,000 new ATTR-CM cases get diagnosed in the U.S. every year now, a number that's climbed as diagnostic imaging has improved and physicians have gotten better at recognizing the condition in older patients presenting with heart failure symptoms that used to get attributed to something else entirely.

In March 2025, Alnylam Pharmaceuticals announced FDA approval for AMVUTTRA as the first RNAi therapy shown to reduce cardiovascular death, hospitalizations, and urgent heart failure visits in adults diagnosed with ATTR-CM. That's a genuinely significant milestone, since it moves the drug's clinical case beyond symptom management into demonstrated impact on the outcomes that actually matter most to patients and their cardiologists.

Transthyretin Amyloidosis Treatment Market Segmentation Analysis

• By Therapy, the Targeted Therapy segment dominated the Transthyretin Amyloidosis Treatment Market with an 87.14% revenue share in 2025, while the Pipeline Therapy segment is the fastest growing.

• By Type, the ATTR-PN segment dominated the Transthyretin Amyloidosis Treatment Market with a 78.25% revenue share in 2025, while the ATTR-CM segment is the fastest growing.

• By Disease, the Wild Type Amyloidosis segment dominated the Transthyretin Amyloidosis Treatment Market with a 54.08% revenue share in 2025, while the Hereditary Transthyretin Amyloidosis segment is the fastest growing with a CAGR of approximately 14.73%.

• By Distribution Channel, the Hospital Pharmacies segment dominated the Transthyretin Amyloidosis Treatment Market with a 52.31% revenue share in 2025, while the Online Pharmacies segment is the fastest growing with a CAGR of approximately 14.76%.

By Therapy, targeted therapy dominates, pipeline therapy grows fastest

Targeted therapy held roughly 87% of the market in 2025, which is a pretty striking number, but it reflects just how thoroughly drugs like Pfizer's Vyndaqel, Alnylam's Onpattro, and Amvuttra have taken over first-line treatment. These drugs go after the root cause of the disease, either stabilizing or silencing the transthyretin protein itself, rather than just managing symptoms, and the clinical results have been strong enough that physicians have made them the default choice almost across the board.

Pipeline therapy is the fastest-growing segment, powered by an unusually active drug development pipeline for a rare disease. BridgeBio's acoramidis and Ionis Pharmaceuticals' eplontersen are two of the more closely watched candidates working through clinical trials right now, both designed to improve on existing efficacy while limiting side effects. With investment in novel ATTR therapies continuing to build, this segment looks positioned to keep growing quickly as new candidates work their way toward approval.

By Type, ATTR-PN dominates, ATTR-CM grows fastest

ATTR with polyneuropathy accounted for about 78% of the market in 2025, driven largely by how common hereditary transthyretin amyloidosis with neurological symptoms turns out to be, and by how much earlier these patients tend to get diagnosed and treated. Approved therapies including patisiran, vutrisiran, and eplontersen have all shown real effectiveness at managing neurological symptoms, which has encouraged fairly widespread adoption among treating physicians.

ATTR-CM is the fastest-growing type, fueled by rising awareness of the cardiac form of the disease and steadily improving diagnostic tools that catch it earlier than used to be possible. New therapies like acoramidis, along with vutrisiran's expanded indication into cardiomyopathy, are opening up meaningful new treatment options, and as the population most at risk for cardiac disease keeps aging, this segment's growth looks set to keep accelerating.

By Disease, wild-type dominates, hereditary grows fastest

Wild-type amyloidosis made up about 54% of the market in 2025, largely a function of how prevalent it is among older adults. It's a condition that used to go underdiagnosed pretty often, but improved diagnostic methods and rising awareness among physicians have brought a lot more of these cases to light, and as the global population keeps aging, incidence keeps climbing right along with it.

Hereditary transthyretin amyloidosis is the fastest-growing disease segment, at a projected CAGR of about 14.73%, as genetic testing becomes more widespread and catches familial cases earlier and more precisely than before. Gene-silencing drugs like patisiran and vutrisiran have meaningfully broadened the treatment landscape for hATTR specifically, and growing government support for orphan drug commercialization is helping keep investment and research flowing into this segment.

By Distribution Channel, hospital pharmacies dominate, online pharmacies grow fastest

Hospital pharmacies led distribution with about 52% share in 2025, mostly because ATTR therapies are complex enough, some requiring intravenous administration under close monitoring, that they're best handled in a clinical setting. Hospital pharmacies are set up for the proper storage, preparation, and administration these treatments need, and they also play a real role in patient education and adherence support that helps these complicated regimens actually integrate into a patient's broader care plan.

Online pharmacies are growing fastest, at a projected CAGR of about 14.76%, as more patients on stable regimens gravitate toward the convenience of home delivery and remote access to their medications. Competitive pricing and expanded reach into underserved or rural populations are helping drive that shift, though ensuring medication authenticity and navigating regulatory requirements remain real priorities for this channel's continued growth.

Regional Analysis

North America Transthyretin Amyloidosis Treatment Market Insights

North America dominated the transthyretin amyloidosis treatment market in 2025 with about 46% of global revenue, owing to established healthcare infrastructure, strong disease awareness, and a concentration of major pharmaceutical and biotechnology companies working in this space. Early access to cutting-edge therapeutics, favorable regulatory backing from the FDA, and heavy investment in rare disease research all keep reinforcing the region's lead.

High diagnosis rates, active clinical trial participation, and solid reimbursement support for new therapies continue driving regional growth. The U.S. accounts for the overwhelming share of that activity, supported by its developed healthcare infrastructure and early uptake of novel therapies, while Canada contributes a smaller, steadier share through its own healthcare system's coverage of specialty treatments.

Get Customized Report as per Your Business Requirement - Enquiry Now

Asia Pacific Transthyretin Amyloidosis Treatment Market Insights

Asia Pacific is the fastest-growing regional market, with a projected CAGR of around 15.68% through 2035, driven by improving healthcare infrastructure, rising healthcare spending, and growing awareness of rare genetic disorders among both clinicians and patients. China, Japan, and India are all seeing increased clinical trial participation and faster regulatory approval of innovative treatments, which is making the region an increasingly attractive target for pharmaceutical companies looking to expand globally.

The sheer size of the region's patient population, much of it still underdiagnosed, means there's substantial unmet need still waiting to be addressed. As diagnostic capabilities keep improving and more physicians become familiar with recognizing ATTR symptoms, the region's growth rate looks likely to keep outpacing every other market covered in this report.

Europe Transthyretin Amyloidosis Treatment Market Insights

Europe holds a meaningful share of the transthyretin amyloidosis treatment market, supported by rising awareness, early diagnosis initiatives, and well-developed healthcare infrastructure across the region. Germany, the UK, and France lead treatment adoption, with Germany specifically benefiting from strong healthcare infrastructure, early embrace of new therapies, and the presence of major pharmaceutical firms operating domestically.

Germany's focus on early diagnosis and comprehensive patient care, combined with favorable regulatory policies, has helped support the distribution and adoption of advanced ATTR treatments across the country. That combination of clinical infrastructure and regulatory support keeps Germany at the front of the European market and should continue supporting steady regional growth through the forecast period.

MEA & Latin America Transthyretin Amyloidosis Treatment Market Insights

Latin America and the Middle East & Africa are both seeing comparatively slow growth in this market. In Latin America, delayed diagnosis, limited access to specialty treatment centers, and the high cost of emerging therapies like RNA interference drugs are the main factors holding back faster adoption, even as awareness of the disease continues to improve gradually.

In the Middle East & Africa, tight regulatory procedures and limited availability of advanced diagnostic equipment are similarly slowing things down. That said, ongoing efforts to build out healthcare infrastructure and raise disease awareness across both regions should support incremental, if unspectacular, market growth over the coming years.

Growth Drivers: Gene-silencing therapies and rising ATTR incidence are reshaping treatment

The approval of gene-silencing therapies like patisiran and vutrisiran has genuinely transformed this market. These drugs work by lowering production of the transthyretin protein responsible for amyloid deposits in the heart and nerves, giving patients access to treatments that can stop or even reverse disease progression rather than just managing symptoms. That's a meaningful departure from conventional therapy, and it's brought real hope to patients who, until recently, had very few options.

At the same time, the aging global population keeps driving up incidence of wild-type ATTR, while hereditary ATTR, which can affect people at a younger age, is adding further demand through improved genetic testing and family screening. Better diagnostic techniques, including nuclear imaging that avoids the need for biopsy, mean more patients are being caught and treated earlier than ever before, and that combination of new therapies and expanding diagnosis is what's driving this market's unusually strong growth rate.

Restraints: Rare disease trials make regulatory approval a genuinely difficult path

Getting regulatory approval for new ATTR therapies is a complicated, often lengthy process, and the disease's rarity makes it worse. With a relatively small pool of eligible patients available for clinical trials, companies can struggle to generate the volume of data regulators like the FDA and EMA typically expect before approving a new treatment.

That data gap makes it genuinely harder for companies to demonstrate safety and efficacy convincingly enough to clear regulatory review, which can slow down promising candidates considerably even when the underlying science looks strong. This challenge is fairly common across rare disease drug development generally, but it's a real and persistent constraint on how quickly new ATTR treatments can reach patients who need them.

Opportunities: Rising diagnosis rates and pipeline activity point toward sustained growth

Advances in nuclear cardiac imaging, particularly technetium pyrophosphate scans that can identify ATTR-CM without a biopsy, are opening up substantial opportunity by catching far more patients than older diagnostic methods ever could. As more patients get identified and referred for treatment, the addressable market for existing and pipeline therapies keeps expanding in a fairly direct way.

An unusually active late-stage pipeline, including candidates like acoramidis and eplontersen, adds further opportunity as these therapies work toward approval and expand the range of treatment options available to physicians. As awareness continues spreading among both clinicians and patients, and as genetic testing becomes more routine for at-risk families, this market looks well positioned for sustained growth well beyond what current approved therapies alone would support.

Recent Developments:

• 2024: In February 2024, BridgeBio Pharma announced that the FDA accepted for review its New Drug Application for acoramidis, an investigational medicine developed to treat ATTR cardiomyopathy.

• 2024: In November 2024, the FDA approved Alnylam Pharmaceuticals' vutrisiran (Amvuttra) as a subcutaneous RNAi therapy for cardiomyopathy caused by wild-type or hereditary transthyretin-mediated amyloidosis in adult patients.

• 2025: In March 2025, Alnylam Pharmaceuticals announced FDA approval for AMVUTTRA as the first RNAi therapy shown to reduce cardiovascular death, hospitalizations, and urgent heart failure visits in adults with ATTR-CM.

Transthyretin Amyloidosis Treatment Market Key Players

• Alnylam Pharmaceuticals, Inc.

• Pfizer Inc.

• Ionis Pharmaceuticals, Inc.

• BridgeBio Pharma, Inc.

• Prothena Corporation plc

• Akcea Therapeutics, Inc.

• Eidos Therapeutics, Inc.

• SOM Biotech

• AstraZeneca plc

• Alexion Pharmaceuticals, Inc.

• Thermo Fisher Scientific Inc.

• Agilent Technologies, Inc.

• Shimadzu Corporation

• Novartis AG

• Roche Holding AG

• Bristol-Myers Squibb Company

• Eli Lilly and Company

• Takeda Pharmaceutical Company Limited

• Sanofi S.A.

• Amgen Inc.

Transthyretin Amyloidosis Treatment Market Report Scope: